Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus E1 protein-specific linear B-cell epitopes, pan-genotype reactivity, and functional relevance.

Frontiers in immunology·2026
Same author

Hepatitis C virus modified <sub>S</sub>E2<sub>F442NYT</sub>-mRNA-LNP candidate vaccine promotes helper CXCR5<sup>+</sup>T cells.

Journal of virology·2025
Same author

Silmitasertib in Combination With Cabozantinib Impairs Liver Cancer Cell Cycle Progression, Induces Apoptosis, and Delays Tumor Growth in a Preclinical Model.

Molecular carcinogenesis·2024
Same author

Increased expression of long non-coding RNA FIRRE promotes hepatocellular carcinoma by HuR-CyclinD1 axis signaling.

The Journal of biological chemistry·2024
Same author

Hepatitis C virus modified sE2<sub>F442NYT</sub> as an antigen in candidate vaccine facilitates human immune cell activation.

Journal of virology·2023
Same author

A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023

Related Experiment Video

Updated: Jun 15, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.1K

Hepatitis C virus chronicity and oncogenic potential: Vaccine development progress.

Yuki Haga1, Sydney Coates1, Ranjit Ray2

  • 1Department of Internal Medicine, Saint Louis University, Missouri, MO, 63104, USA.

Molecular Aspects of Medicine
|August 21, 2024
PubMed
Summary

A prophylactic Hepatitis C virus (HCV) vaccine is crucial for preventing liver disease and cancer. Current treatments like direct-acting antivirals (DAAs) are effective but do not prevent reinfection or HCC risk, necessitating vaccine development.

Keywords:
Antibody class switchingB-cellsCD81Cytokine stimulationEnvelope glycoproteinsHepatitis C virusImmune responseNeutralizing antibodiesT-cellsVaccine strategy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

Related Experiment Videos

Last Updated: Jun 15, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

Area of Science:

  • Hepatology
  • Virology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis C virus (HCV) infection is a global health concern, leading to liver cirrhosis and hepatocellular carcinoma (HCC).
  • Direct-acting antiviral agents (DAAs) have improved HCV treatment outcomes but do not eliminate HCC risk in advanced liver disease or induce lasting immunity, leaving patients susceptible to reinfection.

Purpose of the Study:

  • To review the current understanding of HCV's impact on liver disease and cancer progression.
  • To examine the immune responses involved in HCV infection and host evasion mechanisms.
  • To discuss current strategies and challenges in developing a prophylactic HCV vaccine.

Main Methods:

  • Literature review of scientific publications on Hepatitis C virus.
  • Analysis of immunological data concerning host-pathogen interactions.
  • Synthesis of information on current vaccine development approaches for HCV.

Main Results:

  • HCV infection poses significant risks for liver disease progression and HCC development.
  • DAAs offer therapeutic benefits but do not confer protective immunity against reinfection or fully mitigate HCC risk.
  • HCV employs immune evasion strategies, complicating vaccine-induced immunity.

Conclusions:

  • A prophylactic HCV vaccine is essential for comprehensive HCV control, aiming to induce robust humoral and cellular immunity.
  • Overcoming HCV's immune evasion mechanisms is critical for successful vaccine development.
  • Advancing prophylactic strategies is key to preventing HCV chronicity, liver disease, and HCC.